The combination modulated the TME, reducing immunosuppressive elements and increasing infiltration and activation of CD8+ T cells in subcutaneous and orthotopic models targeting melanoma and colon carcinoma, with combination therapy yielding enhanced tumor regression and survival. The gene discussed is CD8A; the disease is melanoma.